van der Stegen, Sjoukje J. C. http://orcid.org/0000-0002-3839-3124
Lindenbergh, Pieter L. http://orcid.org/0000-0001-8345-2405
Petrovic, Roseanna M.
Xie, Hongyao
Diop, Mame P.
Alexeeva, Vera
Shi, Yuzhe
Mansilla-Soto, Jorge http://orcid.org/0000-0003-2889-1397
Hamieh, Mohamad
Eyquem, Justin http://orcid.org/0000-0001-8262-1190
Cabriolu, Annalisa
Wang, Xiuyan
Abujarour, Ramzey
Lee, Tom http://orcid.org/0000-0001-5846-0075
Clarke, Raedun
Valamehr, Bahram
Themeli, Maria
Riviere, Isabelle
Sadelain, Michel http://orcid.org/0000-0002-9031-8025
Funding for this research was provided by:
New York Stem Cell Foundation
New York Stem Cell Foundation Druckenmiller fellowship
Fate Therapeutics Inc.
Article History
Received: 20 December 2021
Accepted: 28 June 2022
First Online: 8 August 2022
Change Date: 12 February 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41551-024-01181-y
Competing interests
: R.A., T.L., R.C. and B.V. are employees of Fate Therapeutics Inc. and have equity in the company. M.S. reports research funding from Takeda Pharmaceuticals, Atara Biotherapeutics and Fate Therapeutics. M.S. served on the scientific advisory board of St Jude Children’s Research Hospital. Memorial Sloan Kettering has licensed intellectual property on which M.S. is a named inventor to Fate Therapeutics. M.S. does not receive consultation fees or forms of remuneration. The other authors declare no competing interests.